For example, if a provider allows bioprospecting and testing to occur under an ABS contract, and then discovers that the contract is legally invalid, it would be unfair to terminate or unwind the contract, because the return of the genetic material and/or information obtained by the user will not prevent the user from utilizing the information of its research, products or other benefits.